Inhaled Heparin and Low-Cost Drugs Show Promise in Treating Severe COVID-19
A meta-trial across six countries found that inhaled heparin significantly reduces the risk of intubation and death in hospitalized COVID-19 patients, likely due to its antiviral, anti-inflammatory, and anti-coagulant properties, suggesting potential broader applications for respiratory diseases.